BCR and acute lymphoblastic leukemia: The current therapeutic regimen for Ph+ ALL, the combination of chemotherapy with TKIs, does not overcome the major hazard of each individual treatment which are toxicity and development of resistance mutations in the BCR-ABL1 gene.